Reports Q4 revenue $38,000, consensus $110,000. $273M in cash, cash equivalents and short-term investments at end of 2022 and access to a term loan facility of up to an additional $160M provide anticipated runway into the first half of 2026.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATAI:
- atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Rising High: Exclusive talk with house of brands Carma HoldCo
- Rising High: Exclusive talk with cannabinoid market research firm BDSA
- Atai Life Sciences announces corporate updates, reduced workforce by 30%
